Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -225.57% is 36% below its 5-year average of -165.91%, around the middle of its 5-year range (-408.44%–-44.18%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.63% below its 12-month average of -221.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): -225.57%.
RETURN ON EQUITY (ROE)
-225.57%
RETURN ON EQUITY (ROE) AVG TTM
-221.95%
RETURN ON EQUITY (ROE) AVG 3Y
-222.52%
RETURN ON EQUITY (ROE) AVG 5Y
-165.91%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.63%
CURRENT VS 3Y AVG
-1.37%
CURRENT VS 5Y AVG
-35.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 456 covered companies
CURRENT VS SECTOR MEDIAN
-489.73%
vs the sector median at left
Intelligent Bio Solutions Inc.
Market Cap
$5.54M
Return on Equity (ROE)
-225.57%
TTM Avg
-221.95%
3Y Avg
-222.52%
5Y Avg
-165.91%
Market Cap
$5.55M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$5.40M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$5.33M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.31M
Return on Equity (ROE)
-4165.92%
TTM Avg
61.14%
3Y Avg
-23.12%
5Y Avg
-18.15%
Market Cap
$5.21M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
Market Cap
$5.97M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$5.98M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$5.07M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.54M | -225.57% | -221.95% | -222.52% | -165.91% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Alzamend Neuro Inc (ALZN)vs › | $5.40M | -156.77% | -655.11% | -353.82% | -293.10% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.33M | N/A | 383.38% | 131.31% | 101.98% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.31M | -4165.92% | 61.14% | -23.12% | -18.15% |
| Imunon, Inc. (IMNN)vs › | $5.21M | -351.30% | -321.98% | -228.03% | -177.46% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | -92.44% | -28.72% | 10.69% | 23.75% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -87.12% | -90.45% | -143.11% | -272.17% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.07M | -248.66% | -110.63% | -33.84% | -33.84% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.23M | 105.35% | 0.10% | -37.77% | -33.57% |
ROE
-225.6%
ROA
-104.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -225.57% |
| 2026-03-31 | -129.59% |
| 2025-12-31 | -101.81% |
| 2025-09-30 | -300.06% |
| 2025-06-30 | -352.73% |
| 2025-03-31 | -200.70% |
| 2024-12-31 | -245.01% |
| 2024-09-30 | -125.07% |
| 2024-06-30 | -121.94% |
| 2024-03-31 | -90.11% |
| 2023-12-31 | -408.44% |
| 2023-09-30 | -311.89% |
| 2023-06-30 | -279.86% |
| 2023-03-31 | -97.07% |
| 2022-12-31 | -48.70% |
| 2022-09-30 | -121.99% |
| 2022-06-30 | -94.68% |
| 2022-03-31 | -70.07% |
| 2021-12-31 | -65.45% |
| 2021-09-30 | -49.13% |
| 2021-06-30 | -44.18% |
| 2021-03-31 | -35.29% |
| 2020-12-31 | -19.27% |
